A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Start Date26 Jun 2009

Sponsor / Collaborator

Gemin X Pharmaceuticals US, Inc.

NCT00918931

/ TerminatedPhase 2IIT

Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis

The goal of this clinical research study is to learn if obatoclax mesylate can help to control systemic mastocytosis. The safety of this drug will also be tested.

Start Date01 Jun 2009

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT00724841

/ TerminatedPhase 1/2

A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma

Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Start Date01 Jun 2008

Sponsor / Collaborator

Gemin X Pharmaceuticals US, Inc.

100 Clinical Results associated with Gemin X Pharmaceuticals US, Inc.

0 Patents (Medical) associated with Gemin X Pharmaceuticals US, Inc.

Literatures (Medical) associated with Gemin X Pharmaceuticals US, Inc.

01 Jan 2011·Journal of VirologyQ2 · MEDICINE

Genetic Analysis of B55α/Cdc55 Protein Phosphatase 2A Subunits: Association with the Adenovirus E4orf4 Protein

Q2 · MEDICINE

Article

Author: Zhang, Zhiying ; Chan, Francine ; Li, Suiyang ; Roopchand, Diana E. ; Marcellus, Richard C. ; Mui, Melissa Z. ; Berghuis, Albert M. ; Branton, Philip E. ; Blanchette, Paola

ABSTRACT The human adenovirus E4orf4 protein is toxic in both human tumor cells and Saccharomyces cerevisiae . Previous studies indicated that most of this toxicity is dependent on an interaction of E4orf4 protein with the B55 class of regulatory subunits of protein phosphatase 2A (PP2A) and in yeast with the B55 homolog Cdc55. We have found previously that E4orf4 inhibits PP2A activity against at least some substrates. In an attempt to understand the mechanism of this inhibition, we used a genetic approach to identify residues in the seven-bladed β-propeller proteins B55α and Cdc55 required for E4orf4 binding. In both cases, amino-terminal polypeptides composed only of blade 1 and at least part of blade 2 were found to bind E4orf4 and overexpression blocked E4orf4 toxicity in yeast. Furthermore, certain amino acid substitutions in blades 1 and 2 within full-length B55α and Cdc55 resulted in loss of E4orf4 binding. Recent mutational analysis has suggested that segments of blades 1 and 2 present on the top face of B55α form part of the “substrate-binding groove.” Additionally, these segments are in close proximity to the catalytic C subunit of the PP2A holoenzyme. Thus, our results are consistent with the hypothesis that E4orf4 binding could affect the access of substrates, resulting in the failure to dephosphorylate some PP2A substrates.

01 Nov 2009·Molecular and Cellular BiologyQ3 · BIOLOGY

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD⁺ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

Q3 · BIOLOGY

Article

Author: Bédard, Dominique ; Marcellus, Richard ; Nguyen, Mai ; Beauparlant, Pierre ; Lavoie, Manon ; Koch, Elizabeth ; Berger, Alvin ; Roulston, Anne ; Branchaud, Stéphane ; Turcotte, Émilie ; Khadir, Abdelkrim ; Chan, Helen ; Jang, Anne ; Dairi, Kenza ; Gilbert, Karine ; Mitchell, Matthew ; Gratton, Michel-Olivier ; Goulet, Daniel ; Billot, Xavier ; Paquette, Denis ; Watson, Mark ; Lawless, Michael ; Isakau, Henady ; Shore, Gordon C. ; Bernier, Cynthia ; Bélec, Laurent

GMX1777 is a prodrug of the small molecule GMX1778, currently in phase I clinical trials for the treatment of cancer. We describe findings indicating that GMX1778 is a potent and specific inhibitor of the NAD(+) biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT). Cancer cells have a very high rate of NAD(+) turnover, which makes NAD(+) modulation an attractive target for anticancer therapy. Selective inhibition by GMX1778 of NAMPT blocks the production of NAD(+) and results in tumor cell death. Furthermore, GMX1778 is phosphoribosylated by NAMPT, which increases its cellular retention. The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA), which permits NAD(+) repletion via NA phosphoribosyltransferase 1 (NAPRT1). The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot be rescued by NA. Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that high frequencies of glioblastomas, neuroblastomas, and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA. As a result, the therapeutic index of GMX1777 can be widended in the treatment animals bearing NAPRT1-deficient tumors by coadministration with NA. This provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.

01 Sep 2009·Journal of VirologyQ2 · MEDICINE

The Adenovirus E4orf4 Protein Induces G ₂ /M Arrest and Cell Death by Blocking Protein Phosphatase 2A Activity Regulated by the B55 Subunit

Q2 · MEDICINE

Article

Author: Miron, Marie-Joëlle ; Branton, Philip E. ; Zhang, Zhiying ; McQuoid, Monica J. ; Brignole, Claudine ; Binda, Olivier ; Ashby, Danita ; Li, Suiyang ; Thirlwell, Sara ; Marcellus, Richard ; Pallas, David C. ; Chan, Helen

ABSTRACT Human adenovirus E4orf4 protein is toxic in human tumor cells. Its interaction with the Bα subunit of protein phosphatase 2A (PP2A) is critical for cell killing; however, the effect of E4orf4 binding is not known. Bα is one of several mammalian B-type regulatory subunits that form PP2A holoenzymes with A and C subunits. Here we show that E4orf4 protein interacts uniquely with B55 family subunits and that cell killing increases with the level of E4orf4 expression. Evidence suggesting that Bα-specific PP2A activity, measured in vitro against phosphoprotein substrates, is reduced by E4orf4 binding was obtained, and two potential B55-specific PP2A substrates, 4E-BP1 and p70 S6K , were seen to be hypophosphorylated in vivo following expression of E4orf4. Furthermore, treatment of cells with low levels of the phosphatase inhibitor okadaic acid or coexpression of the PP2A inhibitor I 1PP2A enhanced E4orf4-induced cell killing and G 2 /M arrest significantly. These results suggested that E4orf4 toxicity results from the inhibition of B55-specific PP2A holoenzymes, an idea that was strengthened by an observed growth arrest resulting from treatment of H1299 cells with Bα-specific RNA interference. We believe that E4orf4 induces growth arrest resulting in cell death by reducing the global level of B55-specific PP2A activity, thus preventing the dephosphorylation of B55-specific PP2A substrates, including those involved in cell cycle progression.

News (Medical) associated with Gemin X Pharmaceuticals US, Inc.

01 Aug 2024

·avetabiomics.com

Peter R. Dolan, former Chairman and CEO of Bristol Myers Squibb Joins the Board of Aveta Biomics

Peter R. Dolan, former Chairman and CEO of Bristol Myers Squibb Joins the Board of Aveta Biomics Bedford, MA – August 1, 2024 – Aveta Biomics, a pioneering oncology company developing first-in-class, oral immuno-oncology drugs, is pleased to announce that Mr. Peter R. Dolan has joined its Board of Directors. Mr. Dolan has an impressive track record of leadership in the pharmaceutical industry as the former CEO and Chairman of Bristol-Myers Squibb (BMS). His 18 transformative years guiding BMS through significant strategic initiatives brought blockbuster drug Eliquis to its portfolio, and investment in ImClone’s Erbitux, a key treatment for solid tumors, including Head & Neck Cancer. He also licensed the immuno-oncology drug Yervoy, pivotal to BMS’s oncology business, and oversaw substantial investments in biologics. “Joining the board of Aveta Biomics is an exciting opportunity,” said Peter Dolan. “Aveta’s unique approach to cancer treatment, and impressive Phase 2 results can be a potential game-changer. Aveta’s drugs could be both inherently safe and highly effective, without the typical trade-offs seen in cancer treatment. I look forward to collaborating with the board and management to push forward to bring a new class of oncology treatments to the patients.” Mr. Dolan currently chairs the Board of Trustees at Tufts University and the Partnership for A Healthier America. Post-BMS, he successfully led GeminX, an oncology company, to a $225 million acquisition by Cephalon Pharmaceuticals. More recently he served on the Board of Directors of Amplitude Health Care, a Special Purpose Acquisition Company which merged with with Jasper Therapeutics. “We’re beyond excited to have Peter Dolan join our board,” said Dr. Parag G. Mehta, CEO of Aveta Biomics. “Peter has a formidable track record of successes in getting groundbreaking therapies to patients. His strategic insights will help steer Aveta Biomics towards new horizons in cancer treatment and make our big dreams a reality.” Mr. Dolan’s distinguished career includes board roles at American Express, ChildObesity180 (as Chairman), and Dartmouth’s Tuck School Board of Overseers. He holds a BA magna cum laude from Tufts University and an MBA from the Tuck School of Business at Dartmouth College. About Aveta Biomics: Aveta Biomics is an oncology company committed to developing next-generation of safer and highly effective cancer drugs based on mimicking the functions of body’s endogenous metabolites and processes. Aveta’s drugs stimulate the immune system to destroy cancer cells while sparing healthy cells. Aveta is conducting multiple clinical trials for head and neck cancer and glioblastoma. Contact Information: Ms. Hema Gandhi, Media Representative Aveta Biomics betterhealth@avetabiomics.com www.avetabiomics.com

Executive ChangeAcquisition

100 Deals associated with Gemin X Pharmaceuticals US, Inc.

100 Translational Medicine associated with Gemin X Pharmaceuticals US, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 18 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Teglarinad Chloride ( NAMPT )	Lymphoma More	Discontinued
Obatoclax mesylate ( Bcl-2 )	Systemic Mastocytosis More	Discontinued
Temozolomide ( DNA )	Metastatic melanoma More	Discontinued
Bortezomib ( Proteasome )	Mantle cell lymphoma refractory More	Pending
Docetaxel ( PSMA )	Recurrent Non-Small Cell Lung Cancer More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Gemin X Pharmaceuticals US, Inc.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 18 Apr 2025

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing